Posted by Michael Wonder on 01 Sep 2021
MHRA approves Rinvoq (upadacitinib) as first JAK inhibitor in GB for the treatment of both adults and adolescents with moderate to severe atopic dermatitis
31 August 2021 - Approval supported by data from one of the largest registrational Phase 3 programmes in atopic dermatitis evaluating upadacitinib monotherapy or with topical corticosteroids.
AbbVie today announced the Medicines and Healthcare Products Regulatory Agency approved Rinvoq (upadacitinib), an oral JAK inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.
